Bernie Haffey Named Chief Commercial Officer at SightLife Surgical

May 12, 2017: By Joan McKenna

SightLifeSurgicalPaul Bernard “Bernie” Haffey has joined SightLife Surgical as its first chief commercial officer.

SightLife Surgical, founded in 2016, is a Seattle-based for-profit subsidiary of SightLife that provides comprehensive services to support ophthalmic surgeons, from corneal tissue and devices to reimbursement consulting and political advocacy.

“Given our ambitions to accelerate discoveries that will benefit the cornea world, from surgeons to patients, Bernie’s background launching emerging medical technology companies, as well as his proven history of creating shareholder value, will help us reach our goal to eliminate corneal blindness by 2040,” said Monty Montoya, SightLife Surgical president and CEO.

Most recently, Haffey served as president and CEO of Nexis Vision, Inc., and president and CEO of NDO Surgical, Inc. He also served as executive vice president and chief commercial officer at Summit Technology, Inc., and as executive vice president and chief commercial officer at IntraLase Corp. In addition to his role at SightLife, Bernie serves as president of 2020 Management Consulting, Inc.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023